| pubmed-article:10210138 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10210138 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:10210138 | lifeskim:mentions | umls-concept:C0123759 | lld:lifeskim |
| pubmed-article:10210138 | lifeskim:mentions | umls-concept:C1511291 | lld:lifeskim |
| pubmed-article:10210138 | lifeskim:mentions | umls-concept:C1363878 | lld:lifeskim |
| pubmed-article:10210138 | lifeskim:mentions | umls-concept:C1718423 | lld:lifeskim |
| pubmed-article:10210138 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:10210138 | lifeskim:mentions | umls-concept:C1510800 | lld:lifeskim |
| pubmed-article:10210138 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:10210138 | pubmed:dateCreated | 1999-6-16 | lld:pubmed |
| pubmed-article:10210138 | pubmed:abstractText | We have previously demonstrated that intratumoral injection with Ad vectors expressing IL-2 or IL-12 can induce regression in a murine breast cancer model. These IL-2- or IL-12-induced antitumor responses were mainly mediated by Ag-specific T cells. Lymphotactin is a novel lymphocyte chemokine that can cause local accumulation of CD4+, CD8+, and NK cells. We hypothesized that addition of lymphotactin may enhance the antitumor immune responses induced by locally produced IL-2 and IL-12 as we have previously shown. To this end we constructed two double-recombinant adenoviral vectors expressing lymphotactin along with either IL-2 (Ad5 Lym/IL-2) or IL-12 (Ad5 Lym/IL-12). Subcutaneous injection of polyoma middle T (PyMT) or Neu (8142) transgenically derived breast adenocarcinoma cells, in the hind flank of FVB/n mice, results in the formation of tumor nodules in 14-21 days. We show that these constructs elicit potent antitumor responses when administered intratumorally. The antitumor responses are long lasting as determined by rechallenge experiments and hence demonstrate a protective immunity. These observations indicate that by augmenting the antitumor response with adenoviral vectors expressing lymphotactin in combination with IL-2 or IL-12 is a novel way to enhance immunotherapeutic approaches. | lld:pubmed |
| pubmed-article:10210138 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10210138 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10210138 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10210138 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10210138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10210138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10210138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10210138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10210138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10210138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10210138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10210138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10210138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10210138 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10210138 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10210138 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:10210138 | pubmed:issn | 1043-0342 | lld:pubmed |
| pubmed-article:10210138 | pubmed:author | pubmed-author:GauldieJJ | lld:pubmed |
| pubmed-article:10210138 | pubmed:author | pubmed-author:GrahamF LFL | lld:pubmed |
| pubmed-article:10210138 | pubmed:author | pubmed-author:HitzKK | lld:pubmed |
| pubmed-article:10210138 | pubmed:author | pubmed-author:WanYY | lld:pubmed |
| pubmed-article:10210138 | pubmed:author | pubmed-author:MullerW JWJ | lld:pubmed |
| pubmed-article:10210138 | pubmed:author | pubmed-author:ZlotnikAA | lld:pubmed |
| pubmed-article:10210138 | pubmed:author | pubmed-author:EmtageP CPC | lld:pubmed |
| pubmed-article:10210138 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10210138 | pubmed:day | 20 | lld:pubmed |
| pubmed-article:10210138 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:10210138 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10210138 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10210138 | pubmed:pagination | 697-709 | lld:pubmed |
| pubmed-article:10210138 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:meshHeading | pubmed-meshheading:10210138... | lld:pubmed |
| pubmed-article:10210138 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10210138 | pubmed:articleTitle | Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. | lld:pubmed |
| pubmed-article:10210138 | pubmed:affiliation | Department of Pathology, McMaster University, Hamilton, Ontario, Canada. | lld:pubmed |
| pubmed-article:10210138 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10210138 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:10210138 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10210138 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10210138 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10210138 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10210138 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10210138 | lld:pubmed |
